PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
47.13%
Some net income increase while AVXL is negative at -145.83%. John Neff would see a short-term edge over the struggling competitor.
3.87%
Some D&A expansion while AVXL is negative at -0.40%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
17.23%
Some yoy growth while AVXL is negative at -75.36%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
-49.98%
Negative yoy SBC while AVXL is 1345.51%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
93.54%
Slight usage while AVXL is negative at -206.93%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
48.23%
AP growth of 48.23% while AVXL is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might matter for short-term liquidity if expansions are large.
21.18%
Some yoy usage while AVXL is negative at -206.93%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
-49.98%
Negative yoy while AVXL is 437.85%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
33.57%
Some CFO growth while AVXL is negative at -113.39%. John Neff would note a short-term liquidity lead over the competitor.
-2609.70%
Negative yoy CapEx while AVXL is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2609.70%
We reduce yoy invests while AVXL stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
5.36%
Debt repayment growth of 5.36% while AVXL is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
-80.40%
Negative yoy issuance while AVXL is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.